We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Immunovant
IMVT
$8.11B
| $76.3K | ﹤0.01% |
+3,082
| New | +$87.4K |
|
352
CareTrust REIT
CTRE
$9.84B
| $75.8K | ﹤0.01% |
+2,802
| New | +$83.7K |
|
353
Berkshire Hathaway Class B
BRK.B
$1.1T
| $74.8K | ﹤0.01% |
+165
| New | +$76.2K |
|
354
Alvotech
ALVO
$1.21B
| $74.1K | ﹤0.01% |
+5,603
| New | +$69K |
|
355
Sabra Healthcare REIT
SBRA
$5.38B
| $73.7K | ﹤0.01% |
+4,257
| New | +$77.7K |
|
356
PTC Therapeutics
PTCT
$6.26B
| $73.1K | ﹤0.01% |
+1,619
| New | +$69.3K |
|
|
RNAM
357
DELISTED
Avidity Biosciences
RNAM
| $72.8K | ﹤0.01% |
+2,505
| New | +$105K |
|
358
Rhythm Pharmaceuticals
RYTM
$7.25B
| $72.2K | ﹤0.01% |
+1,290
| New | +$71.3K |
|
|
VRNA
359
DELISTED
Verona Pharma
VRNA
| $72.1K | ﹤0.01% |
+1,553
| New | +$58.3K |
|
360
CRISPR Therapeutics
CRSP
$4.77B
| $70.5K | ﹤0.01% |
+1,792
| New | +$84.6K |
|
361
Tanger
SKT
$4.71B
| $67.8K | ﹤0.01% |
+1,987
| New | +$69.2K |
|
362
NovoCure
NVCR
$1.77B
| $67.7K | ﹤0.01% |
+2,272
| New | +$48.1K |
|
363
Citigroup
C
$222B
| $65.6K | ﹤0.01% |
+932
| New | +$62.8K |
|
364
Veracyte
VCYT
$4.77B
| $64.4K | ﹤0.01% |
+1,627
| New | +$61.6K |
|
365
Acadia Pharmaceuticals
ACAD
$4.55B
| $64.1K | ﹤0.01% |
+3,494
| New | +$56.4K |
|
366
Apple Hospitality REIT
APLE
$3.92B
| $63.8K | ﹤0.01% |
+4,156
| New | +$64.4K |
|
367
COPT Defense Properties
CDP
$4.35B
| $63.4K | ﹤0.01% |
+2,047
| New | +$65K |
|
368
Xenon Pharmaceuticals
XENE
$6.2B
| $62.8K | ﹤0.01% |
+1,601
| New | +$66.2K |
|
369
Denali Therapeutics
DNLI
$3.86B
| $61.6K | ﹤0.01% |
+3,022
| New | +$77.4K |
|
370
EPR Properties
EPR
$4.9B
| $60.9K | ﹤0.01% |
+1,376
| New | +$63K |
|
|
MRUS
371
DELISTED
Merus
MRUS
| $60.5K | ﹤0.01% |
+1,438
| New | +$69.1K |
|
|
FOLD
372
DELISTED
Amicus Therapeutics
FOLD
| $59.1K | ﹤0.01% |
+6,274
| New | +$65.2K |
|
373
Janux Therapeutics
JANX
$950M
| $59K | ﹤0.01% |
+1,102
| New | +$58.3K |
|
374
Highwoods Properties
HIW
$3.73B
| $58.9K | ﹤0.01% |
+1,926
| New | +$62.7K |
|
375
National Health Investors
NHI
$3.69B
| $58.2K | ﹤0.01% |
+840
| New | +$63.9K |
|
Similar funds
CM
BP
AAM
CAG
RCG
AL
CGPCS
EAM
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.